Latest Articles

Publication Date
Oxidative stress in endometriosis: Sources, mechanisms and therapeutic potential of antioxidants (Review).

Endometriosis affects ~15% of women of reproductive age worldwide, impacting ~190 million individuals. Despite its high prevalence, the precise pathogenesis of endometriosis remains unclear. Emerging evidence has highlighted oxidative stress …

Published: March 7, 2025, midnight
Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer - OncLive

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer OncLive

Published: March 6, 2025, 2:32 p.m.
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com

Published: March 5, 2025, 11:04 a.m.
Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer - Oncology Nurse Advisor

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer Oncology Nurse Advisor

Published: March 5, 2025, 5 a.m.
Does interdisciplinary group care for the treatment of endometriosis improve pain interference: protocol for a pilot randomised controlled trial at an urban academic medical centre.

Endometriosis affects 10-15% of people assigned female at birth and can cause chronic pelvic pain and impair many domains of quality of life, such as fertility, mood and bladder, bowel …

Published: March 5, 2025, midnight
Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer - Frontiers

Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer Frontiers

Published: March 4, 2025, 1:24 p.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com

Published: Feb. 28, 2025, 10:47 a.m.
Case report of endometrioid carcinoma arising from the paraovarian cyst.

Paraovarian cysts develop near the ovaries and fallopian tubes in the pelvic region. We describe our experience with a case of endometrioid carcinoma arising from a paraovarian cyst to help …

Published: Feb. 28, 2025, midnight
Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective - MSN

Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective MSN

Published: Feb. 24, 2025, 4:36 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!